Cord Blood Program
Dr. Delaney’s primary research interests focus on the growth of umbilical cord blood stem and progenitor cells in the lab for clinical applications. Her goal is to develop therapies that, when administered, improve the outcome of patients who suffer severe side effects related to cord blood transplant or intensive chemotherapy.
Dr. Milano's research is focused on improving the outcomes for cord blood transplant recipients. He has carried out pivotal analyses of outcomes using cord blood versus conventional stem cell sources. His goal is to expand the alternative donor program with an emphasis on identifying novel regimens/stem cell source combinations that are disease specific and can reduce post-transplant mortality and relapse.
Dr. Salit is a clinical scholar focused on the long-term care and outcomes of patients receiving alternative-donor transplants. She also has a specific interest in the use of reduced intensity conditioning regimens for cord blood transplant.
Dr. Dahlberg is a clinical scholar focused on the long-term care and outcomes of patients receiving alternative-donor transplants. She also has a specific interest in the use of our non-HLA matched expanded cell product as a supportive-care measure in pediatric patients.
Dr. Merriam is a postdoctoral fellow whose research is focused on further developing our understanding of the ways that the expanded cell product can protect patients undergoing intensive chemotherapy from severe infectious complications. She also has a particular interest in how the expanded cells interact with the immune system in cord blood transplant patients.
Dr. Stoltzman is a staff scientist whose research is focused on preclinical studies of how the expanded cells can be manipulated to perform new therapeutic functions. She has a specific interest in the expression of chimeric antigen receptors in the expanded cells, and their use against cancers.